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Huntington disease (HD) is a neurodegenerative, autosomal dominant disorder of late-onset, caused by
the expansion of a CAG repeat in the coding region of the gene. Ours is the reference laboratory for
genetic testing in HD, in Portugal, since 1998; 90.1% of all 158 families known were identified for the first
time, including patients with unusual presentation or without family history. A total of 338 genetic tests
were performed: 234 for diagnosis, 96 for presymptomatic and four for prenatal testing (four were done
for family studies). Most referring physicians were neurologists (90.6%); 82.8% of all clinical diagnosis
were confirmed, while 83.1% of those sent for exclusion were in fact excluded. In presymptomatic testing,
an excess of female subjects (59.4%) was again verified; 37.5% of the consultands were found to be
carriers. None of the foetuses, in four prenatal tests, were mutation carriers. One juvenile case was
inherited from her mother. Our patient population is very similar to others described so far, namely in
terms of mean age at onset and (CAG)n distribution, except perhaps for a higher frequency of large normal
(class 2) alleles (3.7%). We also identify cases posing particular problems for genetic counselling, such as,
‘homozygosity’ that can pose a serious ethical dilemma, carriers of large normal alleles, and ‘homoallelism’
for a normal gene, which will demand further procedures and may delay results in presymptomatic and
prenatal testing.
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Introduction
Huntington’s disease (HD) is a progressive neurodegenera-
tive disorder, with onset usually during adult life, asso-
ciated with involuntary choreic movements, motor
problems, cognitive impairment and, often, a personality
disorder tending to depression, anger and temper out-
bursts.1 Prevalence of HD is estimated to be about
5–10:100 000 in individuals of European descent, but is
considered less common in southern Europe.2
HD is a dominant disorder caused by the expansion of a
(CAG)n in the first exon of the HD gene, located on
chromosome 4p16.3.3 The repeat contains (class 1) 6–26
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CAGs in normal, stable alleles; (class 2) 27–35 CAGs in
large normal, but expandable alleles, especially upon
paternal transmission; (class 3) 36–39 CAGs in expanded
alleles with reduced penetrance; and (class 4)X40 CAGs in
fully penetrant alleles.4
UnIGENe is the reference laboratory for HD testing in
Portugal, having thus access to virtually all patients and
families diagnosed since 1998, when diagnostic, presymp-
tomatic and prenatal testing began to be offered. That same
year, the lab entered the external quality assurance scheme
offered by EMQN.5 Recommendations of the UK Clinical
Molecular Genetics Society were adopted for internal
quality assurance. The present results reflect the first 5
years of molecular diagnosis of HD in the country.
This was the first genetic study of HD in Portugal; its
aims were: (1) to characterise clinical presentation, age at
onset, family history, (CAG)n distribution, correlation
between repeat size and age at onset, and geographic
distribution of the HD Portuguese patients; (2) to assess the
rate of positive molecular diagnosis; (3) to identify ‘HD-
like’ patients and families, after exclusion of a molecular
diagnosis of HD; (4) to assess the uptake of presymptomatic
and prenatal testing in the country; and (5) to identify
cases that pose special problems for genetic counselling
and their frequency.
Materials and methods
Ascertainment methods
Requests for testing were received from February 1998 to
the end of December 2002.
Diagnostic tests are always performed upon referral from
a physician, usually a neurologist, for confirmation or
exclusion of a clinical diagnosis or suspicion of HD.
A signed informed consent, and a form with clinical and
family information are requested.
Presymptomatic and prenatal testing was offered only
after adequate counselling and psychosocial evaluation at a
genetics service; a specific consent form is mandatory. For
presymptomatic testing, two blood samples obtained at
different moments are requested. For prenatal testing,
blood samples from both parents are also obtained.
Demographic and clinical data collected from each
patient include signs and symptoms at time of referral,
age of onset and a family history of any neurological and
psychiatric symptoms.
Infantile and juvenile cases were defined as those with an
onset below age 10 years, and between 11 and 19 years,
respectively.6
Subjects
Non-Portuguese patients and families tested for HD (15
families from Brazil, two from Majorca, two from Cape
Verde, one from Angola and one from the UK) were
excluded for this study. A total of 338 samples were
received in individuals of Portuguese origin: 234 for
diagnostic (confirmation or exclusion), 96 for presympto-
matic and four for prenatal testing; four were performed for
family studies. We have thus registered 158 Portuguese
families with HD; for some of the presymptomatic tests, a
confirmation in a proband had been obtained abroad,
before 1998 (the reason why the number of families is
larger than our series of patients).
Methods
Genomic DNA was extracted from blood lymphocytes by
standard methods.7.The CAG repeat size was assessed
by polymerase chain reaction (PCR) analysis, using the
RS1 and WP2 primers, flanking the CAG repeat.8 This was
determined by denaturing 6% polyacrylamide gel electro-
phoresis, with an M13 sequence ladder, and visualized by
autoradiography. The estimated error is71 CAG. We used,
as positive controls, genomic DNA from (1) a patient with
an allele containing 94 CAGs (the largest we have
amplified so far), and from (2) a patient with 17 and 40
CAGs, previously confirmed by sequencing. Cases of
homoallelism (defined as two alleles with exactly the same
number of CAGs) were resolved (1) by PCR, using the RS1
and RS2 primers, which include both the CAG and the
(also polymorphic) CCG repeat;8 and, (2) if the previous
failed (ie, also same number of CCGs), Southern blotting
was performed.9
Statistical analysis
w2 analysis tested different proportions by gender. Student’s
t-test was used to compare mean age at onset or referral in
two groups (male/female, confirmed/nonconfirmed). The
strength of linear correlation between age at onset and
repeat size was calculated by R-squared. A P-value o0.05
was considered statistically significant.
Results
Results of all diagnostic tests
Among all patients sent for diagnostic testing, 127 (54.3%)
were females, having a mean age at request7SD of
53.4716.1 years (range, 12–87); and 107 (45.7%) were
males, with a mean age of 49.1715.5 years (range, 7–75).
A genetic diagnosis of HD was obtained in a total of 151
(64.5%) individuals, with a CAG expansion Z36 repeats
(class 3 or 4). Their mean age was 51.5714.2 years (range,
10–77): 79 (52.3%) were female individuals, with a mean
age of 51.5714.3 years (range, 12–77); and 72 (47.7%)
were male individuals, with a mean age of 51.6714.1 years
(range, 10–75).
In the remaining 83 (35.5% of all requests), an exclusion
of HD was made, as both alleles had CAG sizes of o36
repeats (classes 1 and 2). Their mean age at request was
51.3718.8 years (range, 7–87), and their mean age at onset
was 46.2719.9 years (range, 3–83). This group was
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composed by 48 (57.8%) women, with a mean age of
56.6718.3 years (range, 12–87), and 35 (42.2%) men, with
a mean age of 44.1717.1 years (range, 7–73).
No differences were found, in relation to age at referral,
age at onset, or sex composition, between patients
genetically confirmed or excluded for HD.
Diagnostic tests were mainly requested by neurologists
(90.6%), although other clinicians, such as medical
geneticists (6.4%), neuropediatricians (1.3%), psychiatrists
(0.9%), family physicians (0.4%) and internists (0.4%) have
also sent some requests. The number of all diagnostic
requests increased till 2000 and decreased during 2002.
Requests for confirmation and exclusion of HD
There were 169 requests for molecular confirmation
(patients with a clinical diagnosis of HD), and 65 requests
for exclusion (clinical diagnosis of HD uncertain or doubt-
ful). Patients sent for confirmation of HD had a mean age
at referral of 53.0715.1 years (range, 10–87), and a mean
age at onset of 45.6715.0 years (range, 5–80). Those sent
for exclusion had a mean age of 47.4717.3 years (range,
7–84) and a mean age at onset of 41.6718.5 years (range,
3–83). Mean age was significantly lower for patients sent
for exclusion of HD (P¼0.046); however, no differences
were found in terms of age at onset or sex proportion.
Among all requests sent for molecular confirmation of
HD (n¼169), 140 (82.8%) were actually confirmed, while
29 (17.2%) patients were not (‘false-positive’ cases). Among
these, 15 had family history of a similar disorder, eight had
not, and it was unknown in six (Table 1). Eight patients
with family history had somewhat unusual presentation:
five had only chorea, two had tremor and dysarthria, and
one had only dementia; the remaining seven had a typical
clinical picture, except for a later age at onset (mean 66.4
years). Among eight cases without family history, four had
typical symptoms and four did not (two had only chorea,
one had chorea and generalised hypotonia, and one had
only psychiatric symptoms and tics). In five cases, family
history was not provided.
From all referrals for exclusion of HD (n¼65), 54 (83.1%)
were in fact excluded; 11 (16.9%) patients had a CAG
expansion X36 repeats. Five of these had a family history
(but no proband available), and presented only involun-
tary and choreic movements, without cognitive impair-
ment or motor problems; two had a typical presentation,
but family history absent or unknown; the remaining four
(6.1%) had both family history and a typical presentation
described, and the reasons why the clinical diagnosis had
been questioned were not clear to us.
Presymptomatic and prenatal testing
All requests were received from clinical geneticists or
neurologists in the counselling teams of the national
programme for presymptomatic testing of late-onset dis-
orders.
The mean age of subjects (n¼96) who performed
presymptomatic testing was 38.0713.2 years (range,
19–71): 57 (59.4%) were females, with a mean age of
39.2713.9 years (range, 19–71), and 39 (40.6%) were males,
with a mean age of 36.1712.1 years (range, 19–68). In 74
(77.1%) cases there was a previous confirmation of HD in the
family at our laboratory, whereas in 10 (10.4%) HD had been
confirmed in a relative, but before 1998 (at another lab).
Prior risk was of 75% in two (2.1%) subjects (both parents
were carriers), 50% (parent affected or carrier) in 88
(91.7%), 25% (grandparent or other second degree relative
affected) in five (5.2%), and unknown (HD confirmed, but
no information about the affected relative) in one (1.0%)
individual.
In 48 (55.2%) presymptomatic tests, the molecular
diagnosis had been made in the affected parent, and in
the remaining in another relative. Mean age of transmit-
ting parents was 61.378.5 years (range, 41–77); this was
the father in 35 (36.5%), the mother in 45 (46.9%), and
both in one (1.0%) case; in 15 (15.6%) cases, the sex of the
affected parent was not made available to us.
Among all presymptomatic tests, 87 (90.6%) were the
first such request in their family.
Presymptomatic testing disclosed 36 (37.5%) carriers of
the HD mutation. In all four prenatal tests, the presence of
an allele X36 CAGs was excluded.
HD families
Among all patients confirmed by DNA analysis (n¼151),
121 (80.1%) had a family history of HD, eight (5.3%) had
none and in 22 (14.6%) it was not reported (Table 1).
Table 1 Family history of HD according to test results
Referrals for HD confirmation Referrals for HD exclusion
HD confirmed (X36 CAGs)
HD excluded
(o36 CAGs) HD confirmed (X36 CAGs)
HD excluded
(o36 CAGs) Total
(CAG)n (CAG)n
Family history n (%) Mean SD n (%) n (%) Mean SD n (%) n (%)
Total 140 (82.8) 45.7 7.1 29 (17.2) 11 (16.9) 43.3 3.3 54 (83.1) 234 (100.0)
Present 112 (88.2) 46.2 7.6 15 (11.8) 9 (23.7) 43.4 3.4 29 (76.3) 165 (70.5)
Absent 7 (46.7) 42.3 1.6 8 (53.3) 1 (5.9) 45 F 16 (94.1) 32 (13.7)
Unknown 21 (77.8) 44.6 5.2 6 (22.2) 1 (0.1) 40 F 9 (0.9) 37 (15.8)
Percentages are in relation to the type of request.
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The closest affected relative was the father in 56 (46.3%),
the mother in 31 (25.6%), a sib in 15 (12.4%), a second-
degree relative in five (4.1%) patients and two cousins
(1.7%); no such information was available for 12 (9.9%)
cases. Among those with a family history, this was the first
confirmation of HD in 109 families (90.1%).
A total of 158 unrelated families were thus identified (in
15, we just performed presymptomatic testing; previous
confirmation had been done elsewhere).
The origin of each family was defined as the place
of birth of their oldest known affected individual.
There was no evidence for clustering of HD families in
any particular region; families with HD seemed to be
uniformly distributed, if population density was taken into
account.
CAG repeat length and age of onset
Among all patients confirmed, we had information
about age at onset in 120, with a mean of 43.8713.9 years
(range, 5–73). Three (5, 6 and 7 years) were infantile
and one (19 years) was a juvenile case; 68 had onset
ranging 20–49 years and 32 ranging 50–59 years; and 16
had onset after age 60, up to 73 years. There was no
difference in sex distribution, either overall, or in each of
the age-at-onset groups. We confirmed the inverse correla-
tion between age of onset and (CAG)n size (r
2¼0.49) in our
patients.
Genetic instability of the CAG repeat
Given the recent offer of testing, the number of parent–
offspring pairs is still small (n¼21). In nine paternal
transmissions, the CAG repeat expanded further in six
(mean, þ3.67 CAGs; range, þ2 to þ7) and maintained its
size in three cases. In 12 maternal transmissions, the
(CAG)n expanded further in two (þ1 unit in both),
contracted in four (mean, 1.50; range, 1 to 2) and
kept its size in six cases.
Efficiency of each of the molecular diagnostic
methods
Amplification of the (CAG)n by PCR, with primers RS1 and
WP2, permitted an unequivocal diagnosis in 318 (94.1%)
of all tests (two alleles with different number of CAGs); it
took, on average, 2–3 days. Cases of homoallelism for a
normal gene were resolved using primers RS1 and RS2, in
nine (2.7%) cases; time needed was 5–6 days. The 11
remaining cases of homoallelism (3.2%) were all resolved by
Southern blotting; the whole diagnostic process took about
2 weeks.
Distribution of allele size
We determined the distribution of size of the normal
(CAG)n for all individuals (n¼338) genotyped (all tests).
There were 467 (96.3%) alleles in class 1 (9–26 CAGs); 18
(3.7%) in class 2 (27–32 CAGs). The allele with 17 CAGs
was by far the most frequent among normal alleles
(35.0%), followed by the 18-CAGs (16.5%) and the 20-
CAGs (9.5%) alleles.
The distribution of the disease alleles was determined in
191 subjects. For class 3, n¼7 (3.7%), range 36–39 CAGs;
and for class 4, n¼184 (96.3%), range 40–94 CAGs. The
expanded allele with 42 CAGs was the most common
(18.3%) Figure 1 shows the overall distribution of normal
and disease alleles.
Infantile and juvenile cases
We identified three infantile cases of HD, with CAG
expansions of 67, 90 and 94 units. The affected parent
was the father in all cases; all three, with ages at onset of 5–
7 years, presented with Parkinsonism, rigidity, poor school
and intellectual performance and dementia (Table 2). One
additional case, with a (CAG)66, was referred at the age of
26 years and also presented typical symptoms of infantile
onset, but no information about age at onset, family
history or the affected parent was made available to us.
One juvenile case, with a (CAG)60, had maternal
transmission. She started typical symptoms, after preg-
nancy and delivery at the age of 19 years, including a
movement disorder, memory loss, muscular weakness and
behavioural changes.
Special cases in genetic counselling: ‘homozygosity’
for the HD mutation, carriers of large normal alleles
and ‘homoallelism’ for a normal gene
None of our patients was a ‘full homozygote’, that is,
carrying two fully expanded alleles; however, we identified
two cases, each carrying a fully penetrant (class 4) and a
reduced penetrance allele (class 3): one patient with 51/39
CAGs, and a presymptomatic subject with 47/36 CAGs
(Table 3). The first had onset at 31 years and usual
symptoms; HD was present only on his maternal side; he
had two children, aged 4 and 6 years, a situation that raised
enormous difficulties in genetic counselling. The second
was still asymptomatic by age 24 years, had maternal
family history only, and no progeny.
In addition, four patients (1.7%) had both a fully
penetrant (class 4) and a large normal allele (class 2). All
had a typical clinical presentation and history of HD only
on one side of the family. All patients already had some
offspring.
We have also identified 13 subjects (3.9%) having both a
class 2 and a class 1 allele; seven (2.1%) were male subjects.
We detected 20 cases of homoallelism, 5.9% among all
338 subjects tested; 11 (11.5%) of all presymptomatic tests,
and nine (10.8%) of the patients excluded for HD; 14 were
homoallelic for the most common allele (17 CAGs), four had
both alleles with 18 CAGs, one with 19/19 CAGs, and one
with a 20/20 CAGs genotype.
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Discussion
Offer of molecular diagnosis for HD, in Portugal, started in
1998 and allowed a more precise knowledge about HD,
important namely for the foundation of the Portuguese
Association of Huntington Disease, in 2001. It also allowed
the comparison of ours with other patient populations and
the definition of some difficulties for genetic counselling.
Molecular diagnosis of HD was achieved for the first time
in 90% of all the families. The number of patients and
families reported reflects under-ascertainment, as this
study was not a population-based survey; however, referrals
increased steadily over the first 3 years, stabilised in 2001
and suffered a steep decrease during 2002. This indicates
that we may be approaching a nearly complete ascertain-
ment of families, and that prevalence of HD in Portugal (10
million) may be between 2 and 5:100 000.
Confirmation and exclusion of clinical diagnoses
Most of the diagnostic referrals were made by neurologists
(90.6%), a situation similar to that found in the Nether-
lands (82.2%).10 By contrast, family doctors were predo-
minantly the referring physicians (45.4%) in British
Columbia, where only 37.5% of the referrals were made
by neurologists.11 This can perhaps be explained by the
different systems of medical practice in Europe and
Canada.
The majority of referrals for confirmation of HD were
indeed confirmed. Exclusion of HD in the remaining
patients could be explained by their absent or unknown
family history or by atypical symptoms; however, 4.1% had
both a family history and a typical clinical presentation,
but a later age at onset. This is higher than previously
reported: 2.4%11,12 and 0.8%.10,13 Additional molecular
research of these ‘HD-like’ families is ongoing for known
(HDL114 and HDL215) and unknown loci.
Among all requests for exclusion, a diagnosis of HD
was made in 16.9%. These had often (but not always)
an unusual clinical presentation or absence of family
history.
Characterisation of our patient population
In 5.8% of the patients with known family history, the
closest affected individual was not one of the parents or a
sib, but a second or third-degree relative. These cases could
either imply nonpenetrance (CAG repeat in the smaller
expansion range) or early deaths in their parents, although
we cannot exclude some instances of nonpaternity;
however, at least 5.3% had no family history at all–some
could also result from ‘new’ mutations.
This frequency is within the range of values previously
reported (1–8%),10,11,16 and not far from the estimates that
indicate a mutation rate of 6–14% per generation for the
HD locus.17 ‘New’ mutations would be explained by further
expansion of ‘intermediate alleles’, usually through the
male germ line.18 Frequency of large alleles (class 2),
among all normal chromosomes in our sample (3.7%), was
considerable (although within ranges previously described,
if corrected for the same size intervals.12,19) This prompted
us to undertake a population study of 2000 control alleles,
which showed a similar value (unpublished data).
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Figure 1 Distribution of the (CAG)n size in all 676 alleles
genotyped: normal (classes 1 and 2) and mutated alleles
(classes 3 and 4).
Table 2 Infantile and juvenile cases of HD in Portugal
Patient Sex Age at request
(years)
CAG repeats Age at onset (years) Clinical presentation Affected parent
1 M 10 94/17 6 Parkinsonism, tremor,
bradykinesia
Father
2 F 12 90/17 5 Rigidity, dementia, poor school
performance, walking almost
impossible
Father
3 M 16 67/17 7 Choreic movements,
intellectual capacity decline,
preserved language
Father
4 M 26 66/16 Unknown Parkinsonism, pyramidal
syndrome, dementia,
ophthalmoparesia
Unknown
family history
5 F 24 60/19 19 Movement impairment,
memory and strength loss,
behavioural changes
Mother
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Distribution of expanded repeat size was similar to other
populations.12 Correlation between age at onset and
(CAG)n size (r
2¼0.49), mean age at onset in HD (43.8
years), and that slightly higher in ‘HD-like’ patients (46.2
years), was also in accordance with previous studies.12,20,21
This work illustrates the importance of genotyping
patients with no or unknown family history. Molecular
testing was also particularly helpful for the diagnosis of
later-onset patients (X60 years), 13.3% of all our con-
firmed patients. This is higher than in reports from Wales
(4.7%)22 and England (3.0% 465 years),23 and closer to
that in British Columbia (19.6%).11 The high frequency of
late-onset cases is important for clinicians, and to identify
new families and allow them to be offered presymptomatic
testing.
Four infantile cases were found; at least three were
paternally transmitted. One juvenile case (onset at age 19
years) was inherited from her mother (Table 2).
Presymptomatic testing
Our experience showed a sex ratio (59.4% of female
individuals) in agreement with previous reports.24,25
Possible explanations include a greater involvement of
women in family and reproductive decisions, and their
greater willingness to face difficult decisions and their
consequences. This is also consistent with data from
testing predispositions to cancer.26
As in other reports,25 the number of consultands under
the age of 20 years (all above 18) was very small. The mean
age of those who underwent presymptomatic testing, as
well as the frequency of proven carriers, is also in
agreement with those found in the UK.25 The vast majority
had a prior genetic risk of 50%, as previously described.25
Whenever a person at 25% risk requested testing, it has
always been possible (except in three cases where the at-
risk parent had died) to counsel and test first the parent
still at a 50% risk.
In 12 presymptomatic tests, there was no previous
genetic confirmation of HD in a proband: seven belonged
to three sibships, where all sibs were sampled at the same
time, and at least one was a carrier, thus proving the
existence of a CAG expansion in the family; of the
remaining five, one had an expansion. The four non-
carriers had a family history of HD, but no proband tested–
the report issued mentioned, in each case, the possibility of
genetic heterogeneity and that a risk could not be
completely excluded.
Difficulties in genetic counselling
In addition, homozygosity for HD (defined in the classical
sense of having two mutated alleles), the finding of large
normal alleles, and homoallelism (two alleles exactly of the
same size) presented difficult issues for genetic counselling.
Two homozygous individuals were identified (Table 3): the
first had a typical clinical presentation and age at onset,
while the second is still asymptomatic at the age of 24
years: again, this is in agreement with HD being a
completely dominant phenotype.27,28 Thus, the main
question may be if the counsellor should give the
consultands their exact genotype (two full mutations, or
one fully mutated and one incomplete-penetrance allele),
if this has no predictive value for them. In fact, there is an
ethical dilemma here: knowledge of the full test result is a
right of the consultands and will undoubtedly be impor-
tant for their decision-making regarding future progeny, if
still at a reproductive age; on the other hand, this will
imply giving away the genotype on their (adult, minor
or yet-to-be born) offspring, which goes against existing
guidelines.29
Carriers of both a fully penetrant and a large normal
allele were not infrequent, and needed a special approach
in terms of genetic risks for their progeny. In female
subjects (three cases), the risk for their offspring to be
affected will still be 50%; but the nonaffected offspring
would still be carriers of a large normal allele, which can
give rise to a full mutation in their own progeny, if males.
In our fourth case, a male subject, the risk for his own
offspring was in fact higher than 50%, as the large normal
allele may further expand to an incomplete or full-
penetrance allele in that generation.
Table 3 Cases with one expansion and one intermediate, class 2 (cases 1 and 2) or class 3 (cases 3 to 6), allele
Case Sex Type of request Age at
request
(years)
CAG
repeats
Age at onset
(years)
Clinical presentation Offspring Affected
parent
1 M Diagnostic 36 51/39 31 Choreiform movements,
facial tics
2 (4 and 6 years) Mother
2 F Presymptomatic 24 47/36 F F 0 Mother
3 M Diagnostic 41 52/29 32 Choreic movements, tics,
irritability, cognitive
impairment, loss of weight
2 (6 and 7 years) Father
4 F Diagnostic 55 42/32 50 Choreic movements,
hypotonia
2 (28 and 35 years) Father
5 F Diagnostic 33 49/28 28 Choreic movements,
behavioural changes
3 (5, 16 and 24 years) Mother
6 F Diagnostic 59 43/32 51 Involuntary movements 2 (26 and 28 years) Mother
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Finally, another problem identified was the frequency of
normal homoallelism (5.9%). This implies that further
procedures may delay the results in presymptomatic
testing and cause major difficulties, particularly for
prenatal diagnosis.
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